New blood-based technology overcomes key limitations in solid tumour detection and monitoring

Researchers have unveiled a groundbreaking blood-based testing platform that addresses some of the most significant limitations of current liquid biopsy technologies. The innovative high-throughput multiplex workflow enables highly sensitive characterisation of solid tumours from low-volume blood samples while capturing the biological complexity that often escapes conventional diagnostic approaches.

The innovation comes from the M3Profiler project, entitled ‘Profiling of tumour-derived macrovesicles using an innovative multiplex microfluidic assay using liquid biopsies (m3PROFILER)’ financed by Xjenza Malta, through the FUSION: R&I Technology Development Program (Grant Agreement number: R&I-2020-011T).

The technology is being developed under the leadership of Omnigene Medical Technology Ltd., with scientific validation undertaken by researchers at the University of Malta.

Current blood-based cancer tests frequently struggle to detect the full diversity of tumour cells present within a patient. Solid tumours are inherently heterogeneous, containing multiple cell populations with distinct molecular characteristics. As cancers progress, they also undergo clonal evolution, with new tumour subpopulations emerging over time, particularly in response to treatment. These dynamic changes can lead to disease progression, treatment resistance, and recurrence, yet many existing technologies fail to adequately detect or track them.

The newly developed workflow was specifically designed to address these challenges. By simultaneously measuring multiple tumour characteristics in a single assay, the platform provides a more comprehensive view of tumour biology, capturing both differences within individual tumours and variations between tumours across patient populations.

At the core of the technology is a highly robust multiplex system capable of accurately measuring a minimum of 30 biomarkers or analytical targets in a single test. Each target is supported by up to 50 analytical repeats, delivering exceptional measurement confidence and reproducibility even from low-volume blood samples. This extensive analytical redundancy significantly enhances sensitivity and enables the reliable detection of low-frequency biological signals that may be missed by conventional approaches.

"Our research demonstrated that many current technologies can overlook critical aspects of tumour heterogeneity and clonal evolution," said the development team. "We designed this workflow to reveal these complex biological features, enabling a more complete understanding of disease status and progression from a simple blood sample."

The platform's architecture is inherently scalable, allowing additional biomarkers to be incorporated as new discoveries emerge. This flexibility creates opportunities to expand testing panels and improve the detection of rare or emerging tumour signatures over time.

Importantly, the workflow is not restricted to a single cancer type. The technology has been designed to support a broad range of solid tumours, creating a versatile platform that can be adapted across multiple clinical applications. Researchers believe this tumour-agnostic approach could accelerate the development of more comprehensive liquid biopsy solutions for cancer detection, monitoring, and treatment management.

The ability to detect and monitor diverse tumour populations has important implications for patient care. By capturing molecular changes associated with disease progression and treatment resistance, the platform may enable earlier identification of recurrence, more effective monitoring of minimal residual disease, and potentially earlier detection of cancer before symptoms become apparent.

The high-throughput nature of the workflow also supports large-scale clinical studies and future screening initiatives, providing a practical pathway toward broader implementation in precision oncology.

As the field moves toward increasingly personalised approaches to cancer management, technologies capable of tracking tumour complexity and evolution will become essential. By combining high sensitivity, analytical robustness, scalability, and broad applicability across solid tumour types, this new multiplex platform represents a significant advance in the next generation of non-invasive cancer diagnostics and disease monitoring.